Quantcast
Last updated on April 18, 2014 at 10:25 EDT

Latest Histone deacetylase inhibitor Stories

2014-04-07 08:31:12

New Pre-Clinical Data Presented at AACR Annual Meeting in San Diego SAN DIEGO, April 7, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new pre-clinical data showing the ability of its lead drug candidate Pracinostat to inhibit bladder cancer cell growth and induce activated transcription factor 3 (ATF-3) expression, a potential marker of tumor response. The data...

2014-02-28 08:25:51

SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML). (Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO) "We are very pleased to receive this orphan drug...

2014-02-26 23:22:59

The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013. BCC Research expects the market to grow to $954.3 million by 2018, and register a five-year compound annual growth rate of 21.4% from 2013 to 2018. Wellesley, Mass. (PRWEB) February 26, 2014 According to a new technical market research report Histone Deacetylase Inhibitors: Emerging Markets, from BCC Research (http://www.bccresearch.com), the...

2014-02-24 23:26:06

Australian researchers say the combination of a psychiatry drug with a photosensitizer may work “synergistically” in patients with a certain kind of Non-Hodgkin’s Lymphoma. Raleigh, NC (PRWEB) February 24, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a new article in the Journal of Photochemistry and Photobiology detailing a promising new treatment for people with cutaneous T-cell lymphoma (CTCL), a variety of T-cell Non-Hodgkin’s Lymphoma involving the skin. Patients...

2014-02-05 23:23:28

Repligen Corporation announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Downingtown, PA (PRWEB) February 05, 2014 Repligen Corporation announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Repligen has been advancing a therapeutic research and development program in Friedreich's Ataxia (FA) in which specific HDAC inhibitors have been...

2014-01-27 04:21:37

DUBLIN, January 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/g3pk2m/epigenetics_drugs) has announced the addition of the "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018" [http://www.researchandmarkets.com/research/g3pk2m/epigenetics_drugs ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) "2013 Report on the...

2013-12-11 13:14:42

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University’s Kimmel Cancer Center. The finding, published in the October issue of the Journal of Experimental Therapeutics and Oncology, has led to development of a phase 1/2 clinical trial at Kimmel Cancer Center to test the agent, Romidepsin (Istodax™), in combination with nab-paclitaxel (Abraxane™) chemotherapy...

2013-11-25 14:40:21

2 separate studies yield key findings for the prevention, diagnosis, treatment and cure for the disease Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target...

2013-11-08 08:27:34

SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today announced that it will be presenting Phase 1/2 data on mocetinostat in myelodysplastic syndromes (MDS) at the 55(th) American Society of Hematology Annual Meeting taking place December 7-10 in New Orleans. Data to be presented demonstrates promising clinical responses to the combination of mocetinostat, a novel spectrum selective HDAC inhibitor, with azacitidine (marketed as Vidaza® by...

2013-10-10 12:28:15

SHENZHEN, China, Oct. 10, 2013 /PRNewswire/ -- GNT Biotech and Medicals Corporation announces the grant of an exclusive license from Shenzhen Chipscreen Biosciences Ltd.for the development and commercialization of Chidamide in Taiwan. Chidamide, an oral, selective histone deacetylase (HDAC) inhibitor, is currently being evaluated in Phase II trials by Chipscreen Biosciences in Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL) and Non-Small Cell Lung Cancer patients...